RecruitingNot ApplicableNCT04368039
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
Sponsor
Nicholas Breitborde
Enrollment
20 participants
Start Date
Dec 4, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Eligibility
Min Age: 15 YearsMax Age: 35 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether breathing high levels of oxygen in a normal-pressure environment (normobaric oxygen therapy) can improve symptoms in people who have recently experienced their first episode of psychosis. The idea is that oxygen therapy may support brain healing and improve thinking and mood in the early stages of psychotic illness.
**You may be eligible if:**
- You are 15 to 35 years old
- You have been diagnosed with a schizophrenia-spectrum disorder or a mood disorder with psychotic features
- Your first psychotic episode began less than 5 years ago
- You estimate average intelligence or above (IQ estimated above 70)
- You are a non-smoker and have not smoked for the past 6 months
- You have no thoughts of suicide or self-harm in the past month
**You may NOT be eligible if:**
- You have a history of intellectual disability
- You have been smoking recently (within the last 6 months)
- You have active suicidal thoughts or behavior
- You have medical conditions that may be worsened by supplemental oxygen therapy
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICENormobaric Oxygen
40% FiO2 for 4 weeks
DEVICEPlacebo
21% FiO2 for 4 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04368039
Related Trials
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT0710511121 locations
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT0530306447 locations
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT0736357713 locations
Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia
NCT048710488 locations
Digital Strategies to Advance Help-Seeking Aim 1 and 2
NCT067744301 location